Aisling Capital Management LP Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001766721

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedHealth TiltHigh Turnover how tags are computed

Q2 2026 · 14 positions · Total reported value $471.62M · Top-10 concentration 99.0% · Updated 2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

Turnover: 21.4% · 0 new · 3 cut · 0 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -15.8% · vs SPY -17.9% · Prev Value $471.62M — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): +2.4% · vs SPY +0.3% · Latest Value $299.32M — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q2 2026 13F filing, Aisling Capital Management LP disclosed 14 equity positions with a combined reported value of $471.62M. The filing implies a focused portfolio: its ten largest positions account for 99.0% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q2 2026 were BBIO ($341.83M), GLUE ($37.65M), SNDX ($28.79M). By sector, the heaviest allocations are Health Care 100.0%.

Versus the prior quarter, Aisling Capital Management LP opened 0 new positions, trimmed 3 and fully exited 0, a turnover rate of 21.4% of positions. The portfolio's overlap with the prior quarter was 93% of names.

The largest new positions opened in Q2 2026 were VTVT ($1.88M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q2 2026)

  • VTVT VTV THERAPEUTICS INC · $1.88M

Fully Exited (vs previous quarter)

No tracked position was fully exited this quarter.

Insider Transactions (Form 4)

Latest Aisling Capital Management LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Aisling Capital Management LP is an SEC-registered 13F filer based in New York, NY, United States. As of Q2 2026 it reported 14 US equity positions with a combined value of $471.62M. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • Headquarters: NEW YORK, NY, United States
  • SEC registration: 801-106625 (status: Approved), registered 2015-09-21
  • Regulatory AUM (Form ADV): $716.44M as of 2026-03-27
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 2 private funds
  • Website: aislingcapital.com

Portfolio Structure

  • 14 positions · $471.62M reported value (Q2 2026)
  • Top 10 holdings = 99.0% of reported value
  • Largest position: BBIO (BRIDGEBIO PHARMA INC COM) at 72.5%
  • Average position size: $33.69M

Sector Tilt

  • Health Care 100.0%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 1 new, 1 reduced
  • 12 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall Direction and Market View: Aisling Capital Management LP appears to maintain a cautious stance, with a slight reduction in the position of BRIDGEBIO PHARMA INC (BBIO), a move that suggests a possible concern regarding its growth prospects. However, the fund retained most of its other positions, indicating a defensive approach with a focus on stability. 2. Key Moves: - Reduction: Aisling Capital Management LP reduced its position in BRIDGEBIO PHARMA INC (BBIO) by 9.8% in the quarter. - No Change: The fund held its positions in MONTE ROSA THERAPEUTICS (GLUE), SYNDAX PHARMACEUTICALS INC (SNDX), COMPASS PATHWAYS PLC (CMPS), BICARA THERAPEUTICS INC (BCAX), BridgeBio Oncology Therapeutic (BBOT), SCHOLAR ROCK HLDG CORP (SRRK), UROGEN PHARMA LTD (URGN), BIOMEA FUSION INC (BMEA), and ACLARIS THERAPEUTICS INC (ACRS) constant. 3. Portfolio Structure: - Passive vs. Active: The portfolio appears to be more passive, with a focus on holding rather than actively trading positions. - Sector Bias: A significant portion of the portfolio is invested in the Health Care sector, which indicates a bias towards biotechnology and pharmaceuticals. - Risk Appetite: The risk appetite is moderate, with no significant additions or reductions in high-risk sectors. 4. Per-Holding One-Liner: - BBIO: Biotechnology company focusing on therapies for genetic disorders. - GLUE: Biotechnology company focusing on developing therapies for orphan diseases. - SNDX: Biotechnology company developing treatments for skin cancer and other conditions. - CMPS: Biotechnology company working on therapies for cancer and rare diseases. - BCAX: Biotechnology company developing treatments for neurodegenerative diseases. - BBOT: Subsidiary of BridgeBio Pharma, also involved in biotechnology. - SRRK: Biotechnology company focusing on genetic therapies. - URGN: Biotechnology company working on treatments for urological conditions. - BMEA: Biotechnology company developing therapies for rare genetic diseases. - ACRS: Biotechnology company developing treatments for rare diseases. 5. One-Sentence Style Summary: Aisling Capital Management LP maintained a stable and cautious portfolio, with a focus on the health care sector, reflecting a preference for passive investment strategies and moderate risk appetite.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice.

Sector Allocation

Health Care 100.0%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 4.59M $341.83M 72.48%
72.48%
Reduce
2 1.56M $37.65M 7.98%
7.98%
Hold
3 1.32M $28.79M 6.10%
6.10%
Hold
4 1.43M $20.27M 4.30%
4.30%
Hold
5 568.92K $16.89M 3.58%
3.58%
Hold
6 1.02M $7.76M 1.65%
1.65%
Hold
7 77.03K $4.24M 0.90%
0.90%
Hold
8 108.00K $3.97M 0.84%
0.84%
Hold
9 2.05M $3.01M 0.64%
0.64%
Hold
10 434.45K $2.30M 0.49%
0.49%
Hold
11 325.00K $2.15M 0.46%
0.46%
Hold
12 50.00K $1.88M 0.40%
0.40%
New
13 325.37K $478.29K 0.10%
0.10%
Hold
14 88.61K $404.05K 0.09%
0.09%
Hold

FAQ

What did Aisling Capital Management LP buy in 2026-Q2?

In its 2026-Q2 13F filing, Aisling Capital Management LP reported 14 equity positions worth $471.62M in aggregate; its largest disclosed positions were BBIO ($341.83M), GLUE ($37.65M), SNDX ($28.79M).

How large is Aisling Capital Management LP's portfolio?

Aisling Capital Management LP reported $471.62M of long equity holdings across 14 positions as of 2026-Q2. Top-10 holdings account for 99.0% of reported value.

What is Aisling Capital Management LP's investment style?

HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/aisling-capital-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →